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Introduction
Diffuse myocardial fibrosis (DMF) is a final endpoint in
most cardiac diseases. It is missed by the late gadolinium
enhancement technique. Currently, the only method to
quantify DMF is biopsy, which has risk and is prone to
sampling error.
Purpose
We have developed a new technique Equilibrium Con-
trast CMR (EQ-CMR) - the first clinically applicable,
robust, noninvasive method to quantify DMF and show it
to be accurate against the current gold-standard of surgical
myocardial biopsy.
Methods
The three elements of EQ-CMR are: a bolus of extra-cellu-
lar Gd-DTPA contrast followed by continuous infusion to
achieve equilibrium; a blood sample to measure blood
volume of distribution, Vd(b) (one minus haematocrit);
and CMR to measure pre and post equilibrium T1 (with
heart rate correction). Vd(m) is calculated, reflecting DMF.
Equilibrium acquisition was optimized in 16 individuals
and achieved by a combination of loading bolus and slow
continuous infusion. The T1 measurement technique and
heart rate correction was validated in phantoms against T1
relaxometry and then against blood [Gd-DTPA]. Clinical
validation was in patients undergoing AVR for AS or mye-
ctomy in HCM (n = 18 and 8 respectively). The surgical
biopsies were analyzed using fully automated image anal-
ysis (macros in ImageJ) for picro-sirius red fibrosis quan-
tification on histology. The scan protocol is outlined in
Figure 1.
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Equilibrium was achieved in all patients within 40 min-
utes. The second scan took 5 mins ± 42 secs (9 breath-
holds). The mean histological fibrosis was 20.5% ± 11%
in AS and 17.1% ± 7.4 in HCM (Figure 2). The total Gd-
DTPA dose was 0.14 ± 0.001 mmol/kg. EQ-CMR Vd(m)
correlated strongly with biopsy histological fibrosis: AS: r2
= 0.86, p < 0.001; HCM: r2 = 0.62, p < 0.02; combined r2
= 0.80, p < 0.001 (Figure 3).
Conclusion
We have developed and validated a new technique, EQ-
CMR to measure diffuse myocardial fibrosis. It is a simple,
reliable and clinically.
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